AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TRAX · NASDAQ · Biotechnology

First Tracks Biotherapeutics (TRAX)

Develops antibody programs for autoimmune and inflammatory diseases.

$45.00

Pre-market−0.28 (−0.62%)

At close$45.28(+9.98%)

Watchlist

In millions of USD, except per-share figures

In millions	Q1 FY25Mar 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Cost of revenue	0	0	0
Gross profit	0	0	0
	51	53	35
Research & development	41	34	26
	10	19	9
General & administrative	10	19	0
Operating income	−51	−53	−35
	4	2	2
Interest income	4	2	2
Income before tax	−47	−50	−33
Net income from continuing operations	−47	−50	−33
Net income	−47	−50	−33
EPS, basic	−$1.36	−$1.45	−$0.94
EPS, diluted	−$1.36	−$1.45	−$0.94
Weighted average shares, basic	35	35	35
Weighted average shares, diluted	35	35	35
EBITDA	−51	−53	−35
Depreciation & amortization	1	0	0
EBIT	−51	−53	−35